

# Effective Medicine for All of Your Lymphoma Patients

No Matter Where They Are in the Journey

**LAVERDIA-CA1**  
verdinexor



Declined Referral

<b>Sadie</b>	12 year old	Spayed Female	Aussie / Lab mix
--------------	-------------	---------------	------------------

- **Chief Complaint:** Rapid onset of symptoms including lethargy and loss of appetite.
- **Diagnosis:** Diffuse, large, B-cell lymphoma.
- **Client Perspective:** Concerned that aggressive treatment may further decrease quality of life, family opted not to pursue chemotherapy.
- **Treatment:** LAVERDIA-CA1 prescribed with prednisone may give the family more time than palliative care alone.
- **Outcome:** Stable disease with excellent QOL for 195 days.

## When prednisone alone is not enough

Combine LAVERDIA-CA1 with steroids to turn palliative care into a targeted treatment plan designed to give clients more quality time with their dogs. LAVERDIA-CA1 is safe for dogs taking other medications or receiving other cancer treatments.



Waiting for Specialist Appointment

<b>Scout</b>	10 year old	Neutered Male	Golden Retriever
--------------	-------------	---------------	------------------

- **Chief Complaint:** Owner noticed “swelling” in neck, otherwise happy and healthy.
- **Diagnosis:** Peripheral T-cell lymphoma.
- **Client Perspective:** Immediately confident about pursuing chemotherapy, client learns there’s a 3-week wait to see a specialist.
- **Treatment:** Consulting with specialist, you prescribe LAVERDIA-CA1 to help slow lymphoma progression immediately.
- **Outcome:** Initial partial response with no further progression for 3 weeks before starting CHOP.

## Don't let days pass without treatment

Use LAVERDIA-CA1 to help prevent further advancement of cancer before chemotherapy starts. Unlike prednisone, LAVERDIA-CA1 does not create resistance to cytotoxic drugs and can sensitize cancer cells to improve response to therapy.



Stopped Chemotherapy

<b>Pepper</b>	9 year old	Neutered Male	German Shepherd
---------------	------------	---------------	-----------------

- **Chief Complaint:** Patient completed CHOP 8 months ago, client recognized enlarged lymph node.
- **Diagnosis:** Relapse, diffuse, large, T-cell lymphoma.
- **Client Perspective:** Client can't manage another round of chemotherapy, concerned about side effects and cost.
- **Treatment:** LAVERDIA-CA1 offers another treatment option, with the convenience of at-home administration.
- **Outcome:** Initial partial response followed by stable disease for 196 days.

## Treatment doesn't have to stop

LAVERDIA-CA1 can be used as a rescue therapy for patients that have relapsed or cannot continue traditional chemotherapy due to side effects. Three tablet strengths allow for precise dosing that maximizes therapeutic benefit while minimizing side effects.

**ANIVIVE**

# Do More for Your Lymphoma Patients

LAVERDIA™-CA1 (verdinexor) is helping primary care teams play a bigger role in treating canine lymphoma

**LAVERDIA™-CA1**  
verdinexor

## Start with a Collaborative Consultation

Include a specialist in treatment-option conversations with your clients to facilitate informed decisions tailored to unique patient and family needs.


Primary Care Team

+

Client

+

Specialist



Guidelines like this may not encompass all possible clinical scenarios, especially acute decompensations that may occur while waiting on the referral appointment, so communication across the three stakeholders in those situations is of paramount importance.

Guideline developed by the Anivive Oncology Advisory Board: Phil Bergman DVM, PhD, DACVIM (O); Antonella Borgatti DVM, MS, DACVIM (O), DECVIM-CA; Johnny Chretien DVM, DACVIM (O); Craig Clifford DVM, MS, DACVIM (O); Chad Johannes DVM, DACVIM (SAIM and O); Cheryl London DVM, PhD, DACVIM (O); Kim Selting DVM, MS, DACVIM (O), DACVR (RO); Avenelle Turner DVM, DACVIM (O).